文献速递前列腺增生与排尿功能障碍

ProVee前列腺尿道支架治疗BPH的12个月随机假手术对照试验结果

12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.
PubMed 文献 · J Urol · 2025-12-15

ProVIDE研究是一项前瞻性、随机、双盲、假手术对照试验,评估ProVee永久性前列腺尿道支架治疗BPH相关下尿路症状的安全性和有效性。221名男性按2:1随机分配至ProVee组(150例)或假手术组(71例),主要终点为3个月和12个月IPSS平均改善。

要点

  • 12个月内无器械或操作相关严重不良事件,无新发持续逆行射精或勃起功能障碍

核心结论

  • ProVee前列腺尿道支架治疗可可靠实施,3个月IPSS改善在统计学上优于假手术,且12个月应答持续。

研究设计与样本

  • 前瞻性、随机、双盲、假手术对照研究(ProVIDE),在美国15个中心和美国以外2个中心开展。
  • 共221名男性按2:1随机分配至ProVee组(150例)或假手术组(71例)。
  • 入选标准:年龄≥45岁,IPSS≥13,峰值尿流率<12 mL/s,前列腺体积30至80 cc,前列腺尿道长度≥3.75 cm。

主要发现

  • 12个月内无器械相关或操作相关严重不良事件,无新发持续逆行射精或勃起功能障碍。

关键数值与推荐

  • 主要有效性终点为3个月和12个月IPSS平均改善。

临床怎么用

  • 治疗可在门诊手术中心或办公室环境中进行,术后无需导尿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The ProVee System for benign prostatic hyperplasia is a new generation permanent prostatic urethral stent for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. ProVIDE is a prospective, randomized, double-blind, sham-controlled study evaluating the safety and effectiveness of ProVee against a sham procedure. MATERIALS AND METHODS: Men at least aged 45 years were eligible for the study if they had International Prostate Symptom Score ≥ 13, peak urinary flow rate < 12 mL/s, prostate volume 30 to 80 cc, and prostatic urethral length ≥3.75 cm. Primary effectiveness endpoints were a mean improvement in International Prostate Symptom Score at 3 months and 12 months. Symptomatic improvement, uroflowmetry, quality of life, and sexual function were assessed at follow-up. RESULTS: A total of 221 participants were randomized 2:1 (150 ProVee, 71 sham) at 15 centers in the United States and 2 centers outside the United States. Treatments were performed in an ambulatory surgery center or office setting and required no catheterization postprocedure. Intention-to-treat analyses showed a > 25% mean improvement in International Prostate Symptom Score over sham at 3 months (9.5 vs 5.6, P = .001) and a > 30% mean improvement from baseline to 12 months in the ProVee arm (37.8%, P = .002). There were no device-related or procedure-related serious adverse events through 12 months, and no incidence of de novo sustained retrograde ejaculation or erectile dysfunction. CONCLUSIONS: Treatment with ProVee was reliably performed and resulted in a statistically superior improvement in International Prostate Symptom Score at 3 months compared with a sham procedure with sustained response at 12 months. CLINICAL TRIAL REGISTRATION NUMBER: NCT05186740.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kaplan SA, Parekattil SJ, Wu NZ, et al. 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia. J Urol. 2025. PMID: 41396103. doi:10.1097/JU.0000000000004896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。